Hypoxia inducible factor 1-α expression as a factor predictive of efficacy of taxane/platinum chemotherapy in advanced primary epithelial ovarian cancer

Cancer Letters

Volumn 251, Issue 1, 2007, Pages 164-167

  Nakai, Hidekatsu ^a   Watanabe, Yoh ^a   Ueda, Haruhiko ^a   Hoshiai, Hiroshi ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemotherapy; Epithelial ovarian cancer; HIF 1 ; Prognostic factor

Indexed keywords

CARBOPLATIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PACLITAXEL; PLATINUM; TAXANE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CANCER; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; CARBOPLATIN; EPITHELIAL CELLS; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 34247155290     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2006.11.017     Document Type: Article

References (10)

1. Gruber G., Greiner R.H., Hlushchuk R., Aebersold D.M., Altermatt H.J., Berclaz G., and Djonov V. Hypoxia-inducible factor 1 alpha in high-risk breast cancer: an independent prognostic parameter?. Breast Cancer Res. 6 (2004) 191-198
2. Kurokawa T., Miyamoto M., Kato K., Cho Y., Kawarada Y., Hida Y., Shinohara T., Itoh T., Okushiba S., Kondo S., and Katoh H. Overexpression of hypoxia-inducible-factor 1 alpha (HIF-1alpha) in oesophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Br. J. Cancer 89 (2003) 1042-1047
3. Lidgren A., Hedberg Y., Grankvist K., Rasmuson T., Vasko J., and Ljungberg B. The expression of hypoxia-inducible factor 1 alpha is a favorable independent prognostic factor in renal cell carcinoma. Clin. Cancer Res. 11 (2005) 1129-1135
4. Swinson D.E., Jones J.L., Cox G., Richardson D., Harris A.L., and O'Byrne K.J. Hypoxia-inducible factor-1 alpha in non small cell lung cancer: relation to growth factor, protease and apoptosis pathway. Int. J. Cancer 111 (2004) 43-50
5. Fillies T., Werkmeister R., Van Diest P.J., Brandt B., Joos U., and Buerger H. HIF 1-alpha overexpression indicates a good prognosis in early stage squamous cell carcinomas of the oral floor. BMC Cancer 5 (2005) 84
6. Nakayama K., Kanzaki A., Hata K., Katabuchi H., Okamura H., Miyazaki K., Fukumoto M., and Takebayashi Y. Hypoxia-inducible factor 1 alpha (HIF-1 alpha) gene expression in human ovarian carcinoma. Cancer Lett. 176 (2002) 215-223
7. Birner P., Schindle M., Obermair A., Breitenecker G., and Ober huber G. Expression of hypoxia-inducible factor 1 alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin. Cancer Res. 7 (2001) 1661-1668
8. Escuin D., Kline E.R., and Giannakakou P. Both microtubule-stabilizing and micro tubule-destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function. Cancer Res. 65 (2005) 9021-9028
9. A. du Bios, H.J. Luck, W. Meier, V. Mobus, S. Costa, B. Richter, M. Warm, T. Bauknecht, W. Schroder, S. Olbricht, U. Nitz, C. Jackisch. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer; an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynakologische Onkologie, Ovarian Cancer Study Group. Semin Oncol. 24 (1997) S15-44-52.
10. P.A. Vasey, G.C. Jayson, A. Gordon, H. Gabra, R. Coleman, R. Atkinson, D. Parkin, Paul randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line J, A. Hay, S.B. Kaye. Scottish Gynaecological Cancer Trials Group, Phase III chemotherapy for ovarian carcinoma, J. Natl. Cancer Inst. 96 (2004) 1682-1691.